KALEIDO BIOSCIENCES INC (KLDO) Stock Price, Quote, News and Overview
NASDAQ:KLDO - Nasdaq - US4833471000 - Common Stock
KLDO Quote, Performance and Key Statistics
0.29
-0.01 (-3.69%)
The current stock price of KLDO is 0.29 null. In the past month the price decreased by -81.99%. In the past year, price decreased by -95.54%.
KLDO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 52 | 678.34B | ||
| JNJ | JOHNSON & JOHNSON | 14.56 | 352.15B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 18.56 | 285.92B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 12.63 | 207.36B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 17.8 | 205.34B | ||
| MRK | MERCK & CO. INC. | 9.43 | 184.88B | ||
| PFE | PFIZER INC | 6.86 | 124.89B | ||
| SNY | SANOFI-ADR | 12.95 | 120.47B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.01 | 89.79B | ||
| GSK | GSK PLC-SPON ADR | 6.62 | 73.29B | ||
| ZTS | ZOETIS INC | 25.73 | 69.10B | ||
| HLN | HALEON PLC-ADR | 21.22 | 46.89B |
Related stock screener links
About KLDO
Company Profile
Kaleido Biosciences, Inc. is a clinical-stage healthcare company, which engages in the provision of healthcare services. The company is headquartered in Bedford, Massachusetts and currently employs 76 full-time employees. The company went IPO on 2019-02-28. The Company’s product candidates are Microbiome Metabolic Therapies (MMTs), which are designed to modulate the metabolic output and profile of the microbiome by driving the function and composition of existing microbes. The company is advancing a pipeline of MMT candidates to address a range of diseases and conditions with unmet patient needs. KB109 and KB174 are the MMT candidates for development as prevention of infections caused by multi-drug resistant (MDR) bacteria. Nomination of these candidates resulted from their performance relative to a range of other MMTs in ex vivo screening of microbiome samples from healthy volunteers, as well as microbiome samples from intensive care unit patients in an experimental set-up that specifically focused on determining the potential of MMTs to decrease the relative abundance of a panel of pathogenic bacteria.
Company Info
KALEIDO BIOSCIENCES INC
18 Crosby Dr
Bedford MASSACHUSETTS 98072 US
Employees: 76
Phone: 16176749000.0
KALEIDO BIOSCIENCES INC / KLDO FAQ
What is the stock price of KALEIDO BIOSCIENCES INC today?
The current stock price of KLDO is 0.29 null. The price decreased by -3.69% in the last trading session.
What is the ticker symbol for KALEIDO BIOSCIENCES INC stock?
The exchange symbol of KALEIDO BIOSCIENCES INC is KLDO and it is listed on the Nasdaq exchange.
On which exchange is KLDO stock listed?
KLDO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for KALEIDO BIOSCIENCES INC stock?
12 analysts have analysed KLDO and the average price target is 11.91 null. This implies a price increase of 4006.38% is expected in the next year compared to the current price of 0.29. Check the KALEIDO BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is KALEIDO BIOSCIENCES INC worth?
KALEIDO BIOSCIENCES INC (KLDO) has a market capitalization of 12.36M null. This makes KLDO a Nano Cap stock.
How many employees does KALEIDO BIOSCIENCES INC have?
KALEIDO BIOSCIENCES INC (KLDO) currently has 76 employees.
Is KALEIDO BIOSCIENCES INC (KLDO) expected to grow?
The Revenue of KALEIDO BIOSCIENCES INC (KLDO) is expected to decline by -36.87% in the next year. Check the estimates tab for more information on the KLDO EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy KALEIDO BIOSCIENCES INC (KLDO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of KLDO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of KLDO, evaluating the profitability, health, valuation and growth aspects
- KALEIDO BIOSCIENCES INC (KLDO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- KALEIDO BIOSCIENCES INC (KLDO) Sales and EPS estimates to see what analysts future expectations are.
- KALEIDO BIOSCIENCES INC (KLDO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- KALEIDO BIOSCIENCES INC (KLDO) Insider and Institutional Ownership to learn about the owners and their transactions.
- KALEIDO BIOSCIENCES INC (KLDO) Stock Chart to make your own analysis
- KALEIDO BIOSCIENCES INC (KLDO) Latest news and press-releases to stay up to date.
Does KALEIDO BIOSCIENCES INC (KLDO) stock pay dividends?
KLDO does not pay a dividend.
When does KALEIDO BIOSCIENCES INC (KLDO) report earnings?
KALEIDO BIOSCIENCES INC (KLDO) will report earnings on 2022-05-02.
What is the Price/Earnings (PE) ratio of KALEIDO BIOSCIENCES INC (KLDO)?
KALEIDO BIOSCIENCES INC (KLDO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.16).
What is the Short Interest ratio of KALEIDO BIOSCIENCES INC (KLDO) stock?
The outstanding short interest for KALEIDO BIOSCIENCES INC (KLDO) is 0.17% of its float. Check the ownership tab for more information on the KLDO short interest.
KLDO Technical Analysis
KLDO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to KLDO. Both the profitability and financial health of KLDO have multiple concerns.
KLDO Financial Highlights
Over the last trailing twelve months KLDO reported a non-GAAP Earnings per Share(EPS) of -2.16. The EPS increased by 11.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -8155.92% | ||
| ROA | -180.08% | ||
| ROE | N/A | ||
| Debt/Equity | 0.52 |
KLDO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 77% to KLDO. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of 10.24% and a revenue growth -36.87% for KLDO